Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00957879 · ClinicalTrials.gov registry record · NA
Different Vitamin D Preparations & FGF23 in Humans
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
NCT00957879: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00957879 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00957879, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
Study Summary
Fibroblast growth factor 23 (FGF23) is a new hormone which controls phosphate and vitamin D levels in humans. Excess FGF23 is associated with an increased risk of death in patients with chronic kidney disease. In this study the investigators are investigating the effects of different forms of vitamin D on FGF23 levels in the blood in order to increase our understanding of how this important hormone works.
Interventions
- DIETARY_SUPPLEMENT Calcitriol
- DIETARY_SUPPLEMENT Ergocalciferol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00957879
The ClinicalTrials.gov registry entry for NCT00957879 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Calcitriol is the first listed.
NCT00957879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00957879 about?
NCT00957879 is a clinical study titled "Different Vitamin D Preparations & FGF23 in Humans". Fibroblast growth factor 23 (FGF23) is a new hormone which controls phosphate and vitamin D levels in humans. Excess FGF23 is associated with an increased risk of death in patients with chronic kidney disease. In this study the investigators are investigating the effects of different forms of vitami...
What is the current status of trial NCT00957879?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2009-05. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00957879?
The interventions under investigation include: Calcitriol (DIETARY_SUPPLEMENT), Ergocalciferol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00957879?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.